Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCT03201757 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

523

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizophreniform Disorder
Bipolar I Disorder

Interventions

DRUG: ALKS 3831

Sponsor

Alkermes, Inc.